ClinicalTrials.gg
RecruitingNCT07541599RAMPUpdated May 15, 2026

Reaching Rural Veterans: Applying Mind-Body Skills for Pain Using a Whole Health Telehealth Intervention - UH3

An interventional study of RAMP Program in Chronic Pain, sponsored by Minneapolis Veterans Affairs Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Minneapolis Veterans Affairs Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,283 studies in Chronic Pain with a site in United States — 257 open to participants now, 348 under way, 7 of them phase 3. Chronic Pain · United States.

Planned enrollment
59th of 1,092
500 · median 60
Started
2026
with 66 others
No phase
803 of 1,283
168 open now
Primary completion
2028-12
later than 296 of 347 live
Registered
1,238th of 1,283
by date

Among the 1,283 studies in Chronic Pain with a site in United States, this one is the 59th largest by planned enrollment of the 1,092 interventional ones that give a count, is one of 67 that started in 2026, is one of 803 with no phase, reaches primary completion later than 296 of the 347 other live ones, and was the 1,238th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

257 of the 1,283 studies in Chronic Pain with a site in United States are open now. Recruiting first, the newest first:

252 more — sign in →

All 257 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,283 studies in Chronic Pain with a site in United States, or all of them as a file.
02

Study summary

The goal of the RAMP mind-body program is to provide Veterans with information and tools that can help them manage their pain. The program explores the important connection between our bodies and minds, and how to use this special connection to manage pain more effectively.

Read the detailed description

Our long-term objective is to improve pain management and reduce opioid use among rural patients in the VA. To accomplish this, we will conduct a randomized clinical trial (RCT) to test the effectiveness of an innovative multi-component complementary and integrative intervention, Reaching Rural Veterans: Applying Mind-Body Skills for Pain Using a Whole Health Telehealth Intervention (RAMP) delivered via group telehealth, for improving rural Veterans' pain management, function, and wellbeing, within the VA healthcare system. This project addresses the significant challenge of implementing effective, non-opioid interventions for chronic pain management among rural Veterans, who experience a disproportionate share of the national pain burden, with more chronicity, opioid harms, comorbid mental health conditions and substance abuse, and are prescribed more opioids and have less access to evidence-based, chronic pain care that addresses their "whole-person" or biopsychosocial needs. The RAMP program strategically coalesces multiple evidence based CIH self-management strategies to address rural Veterans' biopsychosocial needs and overcome existing barriers to implementation. Comprised of pain education, mindfulness, pain specific exercises, and cognitive behavioral strategies, the program is cohesive and scalable.

03

Conditions studied

  • Chronic Pain

Browse trials for

Keywords

  • chronic pain
  • complementary therapies
  • models, biopsychosocial
  • rural
  • Veteran
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • rural-dwelling based on U.S. Health Services Research Administration Criteria
  • chronic pain based on two qualifying pain diagnoses in their electronic health record (EHR) within the same diagnostic category, at least 90 days apart, during the previous 2 years
  • self-reported pain on at least most days in the past 3 months
  • Brief Pain Inventory Interference subscale score ≥ 4/10
  • access to a device with internet
  • willingness to engage in intervention-specific procedures (e.g., meet remotely online for sessions)
  • an email address listed in the EHR.

Exclusion criteria

Exclusion Criteria:

  • severe, poorly controlled psychiatric or substance use disorder (identified by chart review)
  • active member of advisory panel for the study
  • enrollment in another research study for pain
  • enrollment in a similar study
  • enrollment in a similar facilitated, multi-week, multi-modal complementary and integrative health program.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Intervention

    Behavioral: RAMP Program

  • No intervention
    Usual Care

Interventions

  • BehavioralRAMP Program

    RAMP is a 9-week program comprised of weekly online group sessions (90 minutes each) with pre-recorded expert-led education videos, mind-body skill training and practice, and facilitated discussions.

06

What researchers measure

Primary outcomes

  1. Pain interference

    Measured using the Brief Pain Inventory (BPI) interference score. Minimum value: 0. Maximum value: 10. Higher scores indicate worse functioning.

    Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.

Secondary outcomes

  1. Pain intensity

    Measured using the Brief Pain Inventory (BPI) intensity score. Minimum value: 0. Maximum value: 10. Higher scores indicate more severe pain.

    Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.

  2. Pain impact

    Measured using the Graded Chronic Pain Scale-Revised (GCPS-R), a six item scale developed to differentiate mild, bothersome, and high-impact chronic pain. Two questions to identify chronic pain and high impact chronic pain; frequency of pain during the prior 3 months and frequency of limitation in activities in the prior 3 months.

    Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.

  3. Quality of life

    Measured using the World Health Organization (WHO) 2-item measure which measures quality of life and satisfaction with health on a 1 to 5 scale.

    Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.

  4. Quality of life

    Measured using the Euro Quality of Life scale, a 5 section questionnaire to assess mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

    Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.

  5. Physical functioning

    Using the PROMIS Physical functioning 6-item short form v2.0 which measures difficulty doing household activities and agreement with statements on health limitations in physical activities on a 1 to 5 scale.

    Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.

  6. Sleep disturbance

    Measured using PROMIS 6-item short form v1.0 which measures sleep quality on a 1 to 5 scale from very poor to very good in addition to agreement with statements on sleep quality on a 1 to 5 scale.

    Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.

  7. Sleep duration

    Participants self-report their hours of sleep per night in the past month.

    Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.

  8. Fatigue

    The PROMIS fatigue 4-item short form v1.0, which measures fatigue over the past 7 days.

    Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.

  9. Participation in Social Roles and Activities

    Measured using the PROMIS 4-item short form v2.0 which measures frequency of trouble doing activities for leisure, work, or with family or friends on a 1 to 5 scale.

    Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.

  10. Anxiety

    Anxiety will be measured using the Generalized Anxiety Disorder-2 survey (GAD-2) which includes 2 questions that are summed for a total score that can range from 0 to 6.

    Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.

  11. Depression

    Depression will be measured using the Patient Health Questionnaire-2 (PHQ-2) which includes 2 questions that are summed for a total score that can range from 0 to 6.

    Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.

  12. Post Traumatic Stress Disorder (PTSD)

    Measured using the Primary Care PTSD Screen for DSM-5, which asks whether the participant has had exposure to a traumatic event, and if yes, asks 5 follow-up yes/no question regarding experiences in the past month.

    Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.

  13. Overall improvement

    Overall improvement will be assessed with the Patient Global Impression of Change (PGIC) which has participants rate their overall change from very much worse to very much improved on a 7-point scale.

    Time frame: Average over 6 months of follow-up, with assessments at 10 weeks and 6 months.

  14. Percentage of participants self-reporting opioid medication use

    Participant self report of opioid medication use.

    Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.

  15. Substance use

    Measured using the Tobacco, Alcohol, Prescription medications, and other Substance (TAPS) survey. The TAPS is comprised of a 4-item screen for substance use.

    Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.

  16. Adverse events

    Participant self-report of any new or worsening health issue while participating in the study. Participants will also be asked to report potential side effects by choosing from a list of known potential risks of exercise and mindfulness interventions.

    Time frame: Average over 6 months of follow-up, with assessments at 10 weeks and 6 months.

07

Study locations

1 of 1 sites recruiting
  • Minneapolis VAMC
    Minneapolis, Minnesota 55417, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The study data will be submitted to the National Institute of Mental Health (NIMH) Data Archive (NDA). Demographic and clinical outcome measures will be collected and shared using common data elements (CDEs ) from the NIH / HEAL CDE repository. Variable naming and permissible response values will be harmonized according to CDEs data dictionary specifications. Documentation to be made publicly available to the research community and will include: 1. The study protocol; 2. information sheet (provided per waiver of documentation of informed consent); 3. data collection forms/case report forms; 4. data dictionary.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Scientific data included in published manuscripts will be available at the time of publication; all other generated scientific data will be shared with the NDA repository no later than the end of the award.

Access criteria: Publications from this research will be made available to the public through the National Library of Medicine PubMed Central website within one year after the date of publication. The research project team and PRISM/Collaboratory Program Coordinating Center will work together in order to offer deidentified or limited data sets that will be available to the public. Where practicable, Limited Datasets (LDSs) will be created and shared pursuant to a Data Use Agreement (DUA) appropriately limiting use of the dataset and prohibiting the recipient from identifying or reidentifying (or taking steps to identify or re-identify) any individual whose data are included in the dataset. No PHI or VA sensitive data will be shared, unless approved by VA Privacy Officers. Only authorized research personnel as approved by the ACOS in agreement with the MPIs, will have access to individually identifiable data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2028, 32 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 32 months is above that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2026
First posted
Apr 21, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07541599
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Responsible party
Diana J. Burgess (Principal Investigator, Minneapolis Veterans Affairs Medical Center) — Principal investigator
First posted
Apr 21, 2026
Start date
Apr 1, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
May 15, 2026

Study contacts

Diana Burgess, PhD
Contact
diana.burgess@va.gov
612-467-1591
Lee Cross, MPH
Contact
lee.cross@va.gov
612-629-7568
Roni Evans, DC, PhD, MS
principal investigator · University of Minnesota
Katherine Hadlandsmyth, PhD
principal investigator · University of Iowa
Diana Burgess, PhD
principal investigator · Minneapolis Veterans Affairs Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion